Quantcast

Latest Renal cell carcinoma Stories

2010-06-14 01:31:00

WAYNE, N.J. and EMERYVILLE, Calif., June 14 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the final analysis of the Phase 3 NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar® (sorafenib) tablets in patients with advanced non-squamous non-small cell lung cancer (NSCLC) showed that the study did not meet its primary endpoint of improving overall survival in the...

2010-06-09 10:00:00

SALT LAKE CITY, June 9 /PRNewswire/ -- GE Healthcare, a unit of the General Electric Company (NYSE: GE), today presented interim phase 2 study results of fluciclatide, in collaboration with the National Cancer Institute (NCI), a federal research agency and part of the National Institutes of Health. Fluciclatide is an integrin-targeted radiopharmaceutical under development for oncology PET imaging. Esther Mena, MD, Associate Investigator at the NCI, presented preliminary data on the uptake...

2010-06-05 16:39:00

EAST HANOVER, N.J., June 5 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS) (1,2). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual...

2010-06-04 07:00:00

CHICAGO, June 4 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the first results from its collaboration with Pfizer Oncology to study early-stage renal cell carcinoma prognosis, which demonstrated a strong correlation between gene expression and recurrence risk in this patient population. The study, which will be presented in an oral presentation tomorrow (8 - 9:30 a.m. CT) at the ASCO annual meeting in Chicago, could lead to the development of a multi-gene...

2010-06-03 08:00:00

ABBOTT PARK, Ill., June 3 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) scientists and independent researchers will highlight the latest clinical trial data on four of Abbott's investigational oncology compounds at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 4-8 in Chicago. The presentations include data on inhibitors of VEGFR and PDGFR, PARP and bcl-2, and a humanized monoclonal antibody directed against CS1. Abbott's oncology pipeline...

2010-06-03 00:20:00

EAST HANOVER, N.J., June 3 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that a Phase III study of Afinitor® (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors), is part of the largest...

2010-06-02 20:33:07

A minimally invasive technique used to destroy kidney tumors with an electrically controlled heating probe showed similar effectiveness as surgical removal of tumors in curbing cancer recurrence rates for up to five years after treatment. In an article available online in the journal Cancer, Dr. Jeffrey Cadeddu, professor of urology and radiology at UT Southwestern Medical Center, reported the outcomes of more than 200 patients who were treated with radiofrequency ablation (RFA). Once the...

2010-06-02 15:25:34

When kidney cancer spreads to other body parts, patients usually receive a poor prognosis. A new Mayo Clinic study examined the benefits of surgical treatment of kidney cancer, specifically renal cell carcinoma, and how patients saw improved prognosis of their cancer. These findings were presented today at the American Urological Association meeting in San Francisco. Each year in the United States, there are about 50,000 new cases of kidney cancer. In adults, the most common type of kidney...

2010-06-02 15:19:48

Kidney cancer is a radiographic diagnosis which means treatment decisions are often made based on the findings of a solid mass on CT or MRI. Unfortunately these tests cannot distinguish the different types of kidney cancers which have variable risks. As more Americans continue to be scanned as part of their evaluation for various ailments and symptoms, the number of kidney tumors found serendipitously has increased such that now up to 70 percent of kidney cancers are discovered incidentally....

2010-06-02 07:00:00

SAN DIEGO, June 2 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced that it will report new data on its proprietary oncology diagnostic platform, a novel technology that forms the basis of the Company's recently announced collaboration with Bayer Schering Pharma AG. The new data will be highlighted in three separate presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago: Analysis of...


Word of the Day
pungle
  • To take pains; labor assiduously with little progress.
This word comes from the Spanish 'pongale,' put it.
Related